Inherited Factor X Deficiency: Molecular Genetics and Pathophysiology

David N Cooper; David S Millar; Adam Wacey; Susan Pemberton; Edward G D Tuddenham

doi:10.1055/s-0038-1657520

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1997; 78(01): 161-172
DOI: 10.1055/s-0038-1657520

Molecular defects in rare bleeding disorders

Schattauer GmbH Stuttgart

Inherited Factor X Deficiency: Molecular Genetics and Pathophysiology

David N Cooper

¹institute of Medical Genetics, University of Wales College of Medicine, Cardiff, UK

,

David S Millar

¹institute of Medical Genetics, University of Wales College of Medicine, Cardiff, UK

,

Adam Wacey

²Thrombosis Research Institute, London, UK

,

Susan Pemberton

³Haemostasis Research Group, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK

,

Edward G D Tuddenham

³Haemostasis Research Group, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK

› Institutsangaben

Abstract

als PDF herunterladen

PDF (412 kb)

Referenzen

References
1 Mammen EF. Factor X abnormalities. Sem Thromb Haemost 1983; 9: 31-44
2 Girolami A. Tentative and updated classification of factor X variants. Acta Haemato 1986; 75: 58-59
3 Denson KWE. Abnormal forms of factor X. Lancet 1969; 2: 1256
4 Fair DS, Edgington TS. Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses. Br J Haematol 1985; 59: 235-248
5 Giddings JC. Coagulation factor synthesis by the liver with special reference to factors V and VIII. In Fondu P, and Thijs O. (eds) Hemostatic Failure in Liver Disease. Martinus Nijhoff Boston. 1984. pp. 05-21
6 Graves CB, Munns TW, Willingham AK, Stauss AW. Rat factor X is synthesized as a single chain precursor inducible by prothrombin fragments. J Biol Chem 1982; 257: 13108-13113
7 Fair DS, Bahnak BR. Human hepatoma cells secrete single chain factor X, prothrombin and antithrombin III. Blood 1984; 64: 194-204
8 Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894
9 Henkens CM, Bom VJ, Van der Schaaf W, Pelsma PM, Sibinga CT, de Kam PJ, Van der Meer J. Plasma levels of protein S, protein C and factor X:effects of sex, hormonal state and age. Thromb Haemost 1995; 74: 1271-1275
10 Stanton C, Wallin R. Processing and trafficking of clotting factor X in the secretory pathway. Effects of warfarin. Biochem J 1992; 284: 25-31
11 Fujikawa K, Titani K, Davie EW. Activation of bovine factor X (Stuart factor): conversion of activation of factor Xaa to Xab. Proc Natl Acad Sci USA 1975; 72: 3359-3363
12 Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994; 269: 3139-3142
13 Altieri DC. Xa receptor EPR-1. FASEB J 1995; 9: 860-865
14 Ambrosini G, Altieri DC. Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem 1996; 271: 1243-1248
15 Gajdusek C, Carbon S, Ross R, Nawroth P, Stem D. Activation of coagulation releases endothelial cell mitogens. J Cell Biol 1986; 103: 419-428
16 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-2320
17 Nicholson AC, Nachman RL, Altieri DC, Summers BD, Ruf W, Edgington TS, Hajjar DP. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996; 271: 28407-2813
18 Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des(l-45) factor Xa at 2.2A resolution. J Mol Biol 1993; 232: 947-966
19 Rezaie AR, Esmon CT. Asp70→Lys mutant of factor X lacks high affinity Ca²⁺ binding site yet retains function. J Biol Chem 1994; 269: 21495-21499
20 Sunnerhagen M, Forsen S, Hoffren A-M, Drakenberg T, Teleman O, Stenflo J. Structure of the Ca²⁺-free GLA domain sheds light on membrane binding of blood coagulation proteins. Nature Struct Biol 1995; 2: 504-509
21 Scandura JM, Ahmad SS, Walsh PN. A binding site on the surface of activated human platelets is shared by factor X and prothrombin. Biochemistry 1996; 35: 8890-8902
22 Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83: 38-42
23 Brinkman H-JM, Mertens K, Holthuis J, Zwart-Huinink LA, Grijm K, Van Mourik JA. The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes. Brit J Haematol 1994; 87: 332-342
24 Ahmad SS, Rawala-Sheikh R, Walsh P. Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 1989; 264: 20012-20016
25 van Diejen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and FVIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442
26 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212
27 Huang Q, Neuenschwander PF, Rezaie AR, Morrissey JH. Substrate recognition by tissue factor-factor VIIa. J Biol Chem 1996; 271: 21752-21757
28 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: Effects of calcium, phospholipids and tissue factor. Biochemistry 1990; 29: 9418-9425
29 Tucker MM, Foster WB, Katzmann JA, Mann KG. A monoclonal antibody which inhibits the factor Va:factor Xa interaction. J Biol Chem 1983; 258: 1210-1214
30 Annamalai AE, Rao RK, Chin HCC. et al Epitope mapping of functional domains of human factor V with murine monoclonal antibodies. Blood 1987; 70: 139-146
31 Skogen WF, Esmon CT, Cox AC. Comparison of coagulation factor Xa and des-(l-44) factor Xa in the assembly of prothrombinase. J Biol Chem 1984; 259: 2306-2310
32 Persson E, Valcarce C, Stenflo J. The γ-carboxyglutamic acid and epidermal growth factor-like domains of factor X. J Biol Chem 1991; 266: 2453-2458
33 Ye J, Esmon CT. Factor Xa-factor Va complex assembles in two dimensions with unexpectedly high affinity: an experimental and theoretical analysis. Biochemistry 1995; 34: 6448-6453
34 Nicolaes GAF, Tans G, Thomassen CLGD, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va^R506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166
35 Hertzberg MS, Ben-Tal O, Furie B, Furie BC. Construction, expression and characterization of a chimera of factor IX and factor X. J Biol Chem 1992; 267: 14759-14766
36 Chattopadhyay A, James HL, Fair DS. Molecular recognition sites on factor Xa which participate in the prothrombinase complex. J Biol Chem 1992; 267: 12323-12329
37 Iino M, Takeya H, Takemitsu T, Nakagaki T, Gabazza EC, Suzuki K. Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen. Eur J Biochem 1995; 232: 90-97
38 Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883
39 Pryzdial ELG, Bajzar L, Nesheim ME. Prothrombinase components can accelerate tissue plasminogen activator-catalyzed plasminogen activation. J Biol Chem 1995; 270: 17871-17877
40 Pryzdial ELG, Kessler GE. Autoproteolysis or plasmin-mediated cleavage of factor Xaa exposes a plasminogen binding site and inhibits coagulation. J Biol Chem 1996; 271: 16614-16620
41 Pryzdial ELG, Kessler GE. Kinetics of blood coagulation factor Xaα autoproteolytic conversion to factor Xaβ. J Biol Chem 1996; 271: 16621-16626
42 Huang Z-F, Wun T-C, Broze GJ. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-26955
43 Lindhout T, Willems G, Blezer R, Hemker HC. Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochem J 1994; 297: 131-136
44 Broze GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-112
45 Ho G, Toomey JR, Broze GJ, Schwartz AL. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor. J Biol Chem 1996; 271: 9497-9502
46 Gitel SN, Medina VM, Wessler S. Inhibition of human activated factor X by antithrombin III and α-proteinase inhibitor in human plasma. J Biol Chem 1984; 259: 6890-6895
47 Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883
48 Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-2800
49 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane bound factor Va by activated protein C. Protein S modulates factor Xa ptotection. J Biol Chem 1988; 263: 14884-14890
50 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-2732
51 Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-1071
52 Koppelman SJ, van’t Veer C, Sixma JJ, Bouma BN. Synergistic inhibition of the intrinsic factor X activation activation by protein S and C4b-binding protein. Blood 1995; 86: 2653-2660
53 Hackeng TM, van’t Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-21058
54 Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: A blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-5102
55 Messier TL, Pittman DD, Long GL, Kaufman RJ, Church WR. Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X. Gene 1991; 99: 291-294
56 Fung MR, Campbell RM, MacGillivray RTA. Blood coagulation factor X mRNA encodes a single polypeptide chain containing a prepro leader sequence. Nucleic Acids Res 1984; 12: 4481-4492
57 Murakawa M, Okamuia T, Kamura T, Kuroiwa M, Harada M, Niho Y. Analysis of the partial nucleotide sequences and deduced primary structures of the protease domains of mammalian blood coagulation factors VII and X. Eur J Haematol 1994; 52: 162-168
58 Stanton C, Ross RP, Hutson S, Wallin R. Processing and expression of rat and human clotting factor X-encoding cDNAs. Gene 1996; 169: 269-273
59 Jagadeeswaran P, Reddy SK, Rao KJ, Hamsabhushanam K, Lyman G. Cloning and characterization of the 5’ end (exon 1) of the gene encoding human factor X. Gene 1989; 84: 517-519
60 Krawczak M, Wacey A, Cooper DN. Molecular reconstruction and homology modelling of the catalytic domain of the common ancestor of the haemostatic vitamin K-dependent serine proteinases. Hum Genet 1996; 98: 351-370
61 Jaye M, Ricca G, Kaplan R, Howk R, Mudd R, Ngo KY, Fair DS, Drohan W. Polymorphism associated with the coagulation factor X gene. Nucleic Acids Res 1985; 13: 8286
62 Hassan HJ, Guerriero R, Chelucci C, Leonardi A, Mattia G, Leone G, Mariani G, Mannucci PM, Peschle C. Multiple polymorphism sites in factor X locus. Blood 1988; 71: 1353-1356
63 Hay CW, Robertson KA, Fung MR, MacGillivray RTA. RFLPs for Pstl and EcoRl in the human blood clotting factor X gene. Nucleic Acids Res 1986; 14: 5118
64 Wallmark A, Rose VL, Ho C, High KA. A NlalV polymorphism within the human factor X gene. Nucleic Acids Res 1991; 19: 4022
65 Scambler PJ, Williamson R. The structural gene for human coagulation factor X is located on chromosome 13q34. Cytogenet. Cell Genet 1985; 39: 231-233
66 Rocchi M, Roncuzzi L, Santamaria R, Archidiacono N, Dente L, Romeo G. Mapping through somatic cell hybrids and cDNA probes of protein C to chromosome 2, factor X to chromosome 13 and αl-acid glycoprotein to chromosome 9. Hum Genet 1986; 74: 30-33
67 Royle NJ, Fung MR, MacGillivray RTA, Hamerton JL. The gene for clotting factor 10 is mapped to 13q32-qter. Cytogenet. Cell Genet 1986; 41: 185-188
68 Miao CH, Leytus SP, Chung DW, Davie EW. Liver-specific expression of the gene coding for human factorX, a blood coagulation factor. J Biol Chem 1992; 267: 7395-7401
69 Bahnak BR, Howk R, Morrissey JH, Ricca GA, Edgington TS, Jaye MC, Drohan WW, Fair DS. Steady state levels of factor X mRNA in liver and HepG2 cells. Blood 1987; 69: 224-230
70 Hung HL, High KA. Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X. J Biol Chem 1996; 271: 2323-2331
71 Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor X. Proc Natl Acad Sci USA 1984; 81: 3699-3702
72 Fung MR, Hay CW, MacGillivray RTA. Characterization of an almost full-length cDNA coding for human blood coagulation factor X. Proc Natl Acad Sci USA 1985; 82: 3591-3595
73 Huang M-N, High KA. Functional characterization of the 5’ regulatory region of the human factor X gene. Thromb Haemost 1991; 65: 726
74 Huang M-N, Hung H-L, Stanfield-Oakley SA, High KA. Characterization of the human blood coagulation factor X promoter. J Biol Chem 1992; 267: 15440-15446
75 Telfer TP, Denson KW, Wright DR. A ’new’ coagulation defect. Br J Haematol 1956; 2: 308-316
76 Hougie C, Barrow HM, Graham JB. Stuart clotting defect. Segregation of a hereditary hemorrhagic state from the heterozygous heretofore called ‘stable factor’ (SPCA, proconvertin factor VII deficiency). J Clin Invest 1957; 36: 485-493
77 Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894
78 Bemardi F, Marchetti G, Patracchini P, Volinia S, Gemmati D, Simioni P, Girolami A. Partial gene deletion in a family with factor X deficiency. Blood 1989; 73: 2123-2127
79 Wieland K, Millar DS, Grundy CB, Mibashan RS, Kakkar VV, Cooper DN. Molecular genetic analysis of factor X deficiency :gene deletion and germline mosaicism. Hum Genet 1991; 86: 273-278
80 Reddy SV, Zhou Z-Q, Rao KJ, Scott JP, Watzke H, High KA, Jagadeeswaran P. Molecular characterization of human factor X_sanAntonio . Blood 1989; 74: 1486-1490
81 Girolami A, Molaro G, Lazzarin M, Brunetti A, Scarpa R. A new congenital haemonhagie condition due to the presence of an abnormal factor X (Factor X Friuli). Study of a large kindred. Br J Haematol 1970; 19: 179-192
82 Girolami A, Sticchi A, Brunetti A. Prothrombin level and activity in the abnormal factor X (Factor X Friuli) hemorrhagic disorder. Thromb Diath Haemhorrag 1971; 25: 147-156
83 Girolami A, Molaro G, Falomo R. Factor X Friuli coagulation disorder. Acta Haematol 1975; 54: 120-125
84 Girolami A, Lazzarin M, Procidano M, Luzzatto G. A family with heterozygous factor X Friuli defect outside Friuli. Blut 1983; 46: 149-155
85 Fair D, Revak D, Edgington T, Girolami A. Structural studies on the factor X Friuli variant. Thromb Haemost 1983; 50: 279-284
86 Fair DS, Revak DJ, Hubbard JG, Girolami A. Isolation and characterization of the factor X Friuli variant. Blood 1989; 73: 2108-2116
87 Kim DJ, Girolami A, James HL. Characterization of recombinant human coagulation factor X Friuli. Thromb Haemost 1996; 75: 313-317
88 James HL, Girolami A, Fair DS. Molecular defect in coagulation factor X Friuli results from a substitution of serine for proline at position 343. Blood 1991; 77: 317-323
89 Rudolph AE, Mullane MP, Porche-Sorbet R, Tsuda S, Miletich JP. Factor X St Louis II. Identification of a glycine substitution at residue 7 and characterization of the recombinant protein. J Biol Chem 1996; 271: 28601-28606
90 Giannelli F, Green PM, Sommer SS, Poon M-C, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Nucleic Acids Res 24: 103-118
91 Bernardi F, Castaman G, Redaelli R, Pinotti M, Lunghi B, Rodeghiero F, Marchetti G. Topologically equivalent mutations causing dysfunctional coagulation factors VII ²⁹⁴Ala→Val) and X (³³⁴Ser→Pro). Hum Molec Genet 1994; 3: 1175-1177
92 Wallmark A, Larson P, Ljung R, Monroe D, High K. Molecular defect (Gla26-Asp) and its functional consequences in a hereditary factor X deficiency (Factor X Malmo 4). Blood 1991; 78 (Suppl. 01) 60a
93 De Stefano V, Leone G, Ferrelli R, Hassan HJ, Macioce G, Bizzi B. Factor X Roma: a congenital factor X variant defective at different degrees in the intrinsic and the extrinsic activation. Brit J Haematol 1988; 69: 387-391
94 Odom MW, Leone G, De Stefano V, Montiel MM, Boland EJ, Anderson J, Jagadeeswaran P. Five novel point mutations:two causing haemophilia B and three causing factor X deficiency. Molec Cell Probes 1994; 8: 63-65
95 Kim DJ, Thompson AR, Nash DR, James HL. Factors X Wenatchee I and ILcompound heterozygosity involving two variant proteins. Biochim Biophys Acta 1995; 1271: 327-334
96 Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stewart D. The structure of a Ca²⁺-binding epidermal growth factor-like domain:its role in protein-protein interactions. Cell 1995; 82: 131-141
97 Messier TL, Wong CY, Bovill EG, Long GL, Church WR. Factor X Stockton: a mild bleeding diathesis associated with an active site mutation in factor X. Blood Coag Fibrinol 1996; 7: 5-14
98 Watzke HH, Lechner K, Roberts HR, Reddy SV, Wesch DJ, Friedman P, Mahr G, Jagadeeswaran P, Monroe DM, High KA. Molecular defect (Gla^+14→Lys) and its functional consequences in a hereditary factor X deficiency (Factor X “Vorarlberg”). J Biol Chem 1990; 265: 11982-11989
99 Kim DJ, Thompson AR, James HL. Factor X Ketchikan: a variant molecule in which Gly replaces a Gla residue at position 14 in the light chain. Hum Genet 1995; 95: 212-214
100 Watzke HH, Wallmark A, Hamaguchi N, Giardina P, Stafford DW, High KA. Factor X Santo Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 1991; 88: 1685-1689
101 Racchi M, Watzke HH, High KA, Lively MO. Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum. J Biol Chem 1993; 268: 5735-5740
102 Nothwehr SF, Gordon JI. Targeting of proteins into the eukaryotic secretory pathway: signal peptide structure/function relationships. BioEssays 1990; 12: 479-484
103 Greer J. Comparative modelling methods application to the family of the mammalian serine proteases. Proteins Struct Funct Genet 1990; 7: 317-334
104 Wallmark A, Ho C, Monroe DM, Tengbom L, High KA. Molecular defect in F.X ‘Öckerӧ’, a mild congenital F.X deficiency. Thromb Haemost 1991; 65: 1263
105 Marchetti G, Castaman G, Pinotti M, Lunghi B, Di Iasio MG, Ruggieri M, Rodeghiero F, Bemardi F. Molecular bases of CRM+ factor X deficiency:a frequent mutation (Ser334Pro) in the catalytic domain and substitution (Glul02Lys) in the second EGF-like domain. Brit J Haematol 1995; 90: 910-915
106 Tuddenham EGD, Cooper DN. The Molecular Genetics of Haemostasis and its Inherited Disorders. Oxford University Press; 1994
107 Furie B, Furie BC. Molecular basis of coagulation. Cell 1988; 53: 505-518
108 Fernlund P, Stenflo J. Beta-hydroxyaspartic acid in vitamin K- dependent proteins. J Biol Chem 1983; 258: 12509-12512
109 Nakagawa H, Takahashi N, Fujikawa K, Kawamura Y, lino M, Takeya H, Ogawa H, Suzuki K. Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. Glycoconjugate J 1995; 12: 173-181
110 Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor X. J Biol Chem 1993; 268: 3048-3051
111 Bharadwaj D, Harris RJ, Kisiel W, Smith KJ. Enzymatic removal of sialic acid from human factor IX and factor X has no effect on their coagulant activity. J Biol Chem 1995; 270: 6537-6542
112 Liebman HA, Furie BC, Furie B. The factor IX phospholipid- binding site is required for calcium-dependent activation of factor factor IX by factor XIa. J Biol Chem 1986; 262: 7605-7612
113 Morita T, Jackson CM. Preparation and properties of derivatives of bovine factor X and factor Xa from which the ϒ-carboxyglutamic acid domain has been removed. J Biol Chem 1986; 261: 4015-23
114 Persson E, Selander M, Linse S, Drakenberg T, Ohlin A-K, Stenflo J. Calcium binding to the isolated β-hydroxyaspartic acid-containing epidermal growth factor-like domain of bovine factor X. J Biol Chem 1989; 264: 16897-1904
115 Selander-Sunnerhagen M, Persson E, Dahlqvist I, Drakenberg T, Mayhew M, Robin M, Handford P, Tilley JW, Campbell ID, Brownlee GG. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J Biol Chem 1993; 268: 23339-44
116 Valcarce C, Holmgren A, Stenflo J. Calcium-dependent interaction between γ-carboxyglutamic acid-containing and N-terminal epidermal growth factor-like modules in factor X. J Biol Chem 269: 26011-26016
117 MacGillivray RTA, Fung MR. Molecular biology of factor X. Bailliere’s Clin.Haematol 1989; 2: 897-917
118 Bezeaud A, Miyata T, Helley D, Zeng YZ, Kato H, Aillaud MF, Juhan-Vague I, Guillin MC. Functional consequences of the Ser334→Pro mutation in a human factor X variant (factor X Marseille). Eur J Biochem 1995; 234: 140-147